Antibody Gene Selection Through Deep Sequencing and Mass Spectrometry
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing methods for developing monoclonal antibodies and antibody fragments are inefficient, costly, and limited by the size and production complexity of traditional hybridoma technologies, and alternative display systems like phage and yeast display suffer from clonal diversity loss and library instability.
Innovation Solution
A method involving deep sequencing of genomic DNA or mRNA from immunized animals, combined with mass spectrometry, to identify and isolate antibody or antibody fragment encoding genes, reducing the need for physical screening and improving efficiency by using host cell-based antigen presentation and affinity chromatography.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional hybridoma technology is used to develop monoclonal antibodies, then high specificity and affinity are achieved, but the process is inefficient, costly, and time-consuming
Solution Approach 1:
The patent replaces traditional mechanical/physical screening methods (ELISA, flow cytometry, cell sorting) with next-generation sequencing technology to identify antibody genes. This substitution enables high-throughput analysis of antibody repertoires, dramatically increasing development efficiency while maintaining the ability to identify high-specificity antibodies through sequence analysis and in silico prediction
Solution Approach 2:
The patent changes the detection parameter from functional activity measurement (binding assays) to sequence information analysis. By sequencing antibody variable regions and analyzing amino acid sequences, the method identifies antigen-specific antibodies without requiring functional screening, thus improving productivity while preserving reliability through sequence-based specificity assessment
2Reliability
If monoclonal antibodies are used as capture reagents, then high specificity is achieved, but the large size (150 kDa) limits use when multiple binding reagents compete for space
Solution Approach 1:
The patent segments the monoclonal antibody into smaller functional units by identifying and isolating antibody variable region genes (VH, VL, or VHH domains). These variable regions contain the antigen-binding site but lack the large constant regions, resulting in smaller molecules that retain specificity while enabling multiple reagents to access closely spaced epitopes
Solution Approach 2:
The patent extracts only the essential antigen-binding variable regions from complete monoclonal antibodies. By sequencing and isolating V gene sequences, the method produces minimal antibody fragments (such as scFv or VHH) that contain the specificity-determining regions without the bulk of the full antibody structure, thus reducing size while maintaining binding specificity
3Ease of manufacture
If phage display or yeast display systems are used to generate antibody libraries, then production complexity is reduced, but clonal diversity is lost and library stability deteriorates
Solution Approach 1:
The patent creates in silico copies of antibody repertoires by sequencing DNA or RNA from immunized animals and generating digital sequence libraries. These in silico libraries can be analyzed computationally without physical manipulation, preserving the complete diversity of the original repertoire while enabling stable, reproducible analysis through bioinformatics rather than unstable biological systems
Solution Approach 2:
The patent replaces biological display systems (phage, yeast) with computational analysis of sequenced antibody genes. By using next-generation sequencing to capture the entire antibody repertoire and analyzing sequences in silico, the method eliminates the instability and diversity loss inherent in biological display systems while maintaining ease of manufacture through standardized sequencing protocols
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach significantly reduces the time, cost, and effort required for antibody identification, enabling the isolation of high-quality antibodies and fragments, such as VHH domains, without the need for traditional expression and display methods.
Implementation Method 1
analyzing the sequences of the isolated antibodies or their fragments by a protein sequencing procedure, such as mass spectrometry
Implementation Method 2
affinity chromatography
Data Source
AI summary
A multi-step method is disclosed for efficient selection of antibody or antibody fragments. In addition to the dramatically increased efficiency of finding antibodies against a given immunogen by the invented processes, the novel technology also differs from all previously known technologies in that the antibody or antibody fragments represent the most abundant antibodies induced by the immunogen, therefore having the highest potential of specificity and affinity. Utility of the invention can be found in virtually all areas that involve antibody or T cell receptor selection using any animal, against any immunogen.